Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scan tracer could unlock secrets of stress and anxiety

NCT ID NCT03520543

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times

Summary

This completed Phase 1 study tested a radioactive tracer called [11C]Yohimbine in 16 healthy men to see how it binds to alpha2-adrenergic receptors in the brain using PET scans. The goal was to model the tracer's movement and measure its binding, as well as test how a drug called clonidine blocks its uptake. This research aims to improve brain imaging techniques for studying conditions like anxiety and depression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Service de Neurologie C - Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, GHE

    Bron, 69500, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

[11C]Yohimbine (a radioactive tracer for PET scans)

What this could lead to

If successful, this could improve how doctors use PET scans to study brain receptors, potentially aiding research into conditions like depression or anxiety.

What could go wrong

This is a very early, small study in only 16 healthy men, so results may not apply to patients or lead to any direct treatment. The tracer is radioactive, though doses are low.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.